Abstract
The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia’s longest serving medical research institute. WEHI’s High Throughput Screening (HTS) Facility was established in 2003 with $5 million of infrastructure funds invested by WEHI, and the Victorian State Government’s Strategic Technology Initiative through Bio21 Australia Ltd. The Facility was Australia’s first truly academic HTS facility and was one of only a handful operating in publicly funded institutions worldwide at that time. The objectives were to provide access to enabling HTS technologies, such as assay design, liquid handling automation, compound libraries and expertise to promote translation of basic research in a national setting that has a relatively young biotech sector and does not have a big Pharma research presence. Ten years on and the WEHI HTS Facility has participated in over 92 collaborative projects, generated over 18 million data points, and most importantly, projects that began in the Facility have been commercialized successfully (due to strong ties with Business Development and emphasis on intellectual property management) and now have molecules progressing in clinical trials.
Keywords: Academic, cancer, chemical libraries, HTS, malaria, therapeutics, trypanosomiasis.
Combinatorial Chemistry & High Throughput Screening
Title:A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research – Eighteen Million Assays and Counting
Volume: 17 Issue: 3
Author(s): Kurt Lackovic, Guillaume Lessene, Hendrik Falk, Karl-Johan Leuchowius, Jonathan Baell and Ian Street
Affiliation:
Keywords: Academic, cancer, chemical libraries, HTS, malaria, therapeutics, trypanosomiasis.
Abstract: The Walter and Eliza Hall Institute of Medical Research (WEHI) is Australia’s longest serving medical research institute. WEHI’s High Throughput Screening (HTS) Facility was established in 2003 with $5 million of infrastructure funds invested by WEHI, and the Victorian State Government’s Strategic Technology Initiative through Bio21 Australia Ltd. The Facility was Australia’s first truly academic HTS facility and was one of only a handful operating in publicly funded institutions worldwide at that time. The objectives were to provide access to enabling HTS technologies, such as assay design, liquid handling automation, compound libraries and expertise to promote translation of basic research in a national setting that has a relatively young biotech sector and does not have a big Pharma research presence. Ten years on and the WEHI HTS Facility has participated in over 92 collaborative projects, generated over 18 million data points, and most importantly, projects that began in the Facility have been commercialized successfully (due to strong ties with Business Development and emphasis on intellectual property management) and now have molecules progressing in clinical trials.
Export Options
About this article
Cite this article as:
Lackovic Kurt, Lessene Guillaume, Falk Hendrik, Leuchowius Karl-Johan, Baell Jonathan and Street Ian, A Perspective on 10-Years HTS Experience at the Walter and Eliza Hall Institute of Medical Research – Eighteen Million Assays and Counting, Combinatorial Chemistry & High Throughput Screening 2014; 17 (3) . https://dx.doi.org/10.2174/1386207317666140109122450
DOI https://dx.doi.org/10.2174/1386207317666140109122450 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcriptomics in Cancer - Stages Toward Patents in Biomarkers
Recent Patents on Biomarkers Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Gut Inflammation in Response to Injury: Potential Target for Therapeutic Intervention
Recent Patents on Anti-Infective Drug Discovery Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats
Drug Metabolism Letters Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Hormones and the Autonomic Nervous System are Involved in Suprachiasmatic Nucleus Modulation of Glucose Homeostasis
Current Diabetes Reviews Vinorelbine in Cancer Therapy
Current Drug Targets Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe
Current Drug Metabolism Modulation of MMP-9 Pathway by Lycopene in Macrophages and Fibroblasts Exposed to Cigarette Smoke
Inflammation & Allergy - Drug Targets (Discontinued) Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Preliminary In-Vitro Cytotoxic Activity of Novel Substituted diaryl-imidazo [2,1,b]-benzothiazole Derivatives
Letters in Drug Design & Discovery Recombinant Protein Based Therapeutics for IPF
Inflammation & Allergy - Drug Targets (Discontinued)